Evaluating Safety and Efficacy of VV119 in Acute Schizophrenia Adults

NCT07703956 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: VV119 2mg
DRUG: VV119 4mg
DRUG: VV119 6mg
DRUG: Aripiprazole tablet
DRUG: Placebo

Sponsor

Vigonvita Life Sciences